Conference Coverage

Video: Eltrombopag boosted standard therapy in severe, newly-diagnosed aplastic anemia


 

AT ASH 2015

References

ORLANDO – Adding eltrombopag to standard immunosuppressive treatment for newly-diagnosed severe aplastic anemia boosted overall response rates from around 65% to over 90%, based on a late-breaker study presented by Dr. Danielle M. Townsley at the annual meeting of the American Society of Hematology.

Dr. Townsley said that starting the combination treatment immediately at diagnosis, rather than waiting to introduce eltrombopag at either 2 weeks or 3 months after initiating standard immunosuppressive therapy, was associated with better outcomes. As a result of the findings, a cohort extension of the trial will continue and is enrolling patients.

In our video interview, Dr. Townsley discusses the top-level results and says that it’s too early to introduce the protocol into practice outside a clinical trial. She urges hematologists to enroll their patients in the ongoing cohort study.

mdales@frontlinemedcom.com

On Twitter @maryjodales

The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel.

Recommended Reading

NHLBI expert panel issues guideline on sickle cell disease
MDedge Pediatrics
Sickle cell anemia trial halted because of early success
MDedge Pediatrics
Stem cells from sickle cell disease patients used to generate gene-corrected cells
MDedge Pediatrics
Hydroxyurea boosts O2 saturations in children with sickle cell disease
MDedge Pediatrics
Antibiotics to reduce microbiota may improve treatment of sickle-cell disease
MDedge Pediatrics
ASH: Oral drug offers alternative to lifelong transfusions in sickle cell
MDedge Pediatrics
VIDEO: RBCs have extended shelf life, randomized trial shows
MDedge Pediatrics
ASH: Novel GBT440 reduces sickle cells, improves hematologic parameters
MDedge Pediatrics
VIDEO: Novel GBT440 improves blood parameters in sickle cell disease
MDedge Pediatrics
ASH: Prasugrel does not reduce vaso-occlusive crises in sickle cell anemia
MDedge Pediatrics